Search the Newsreel

General Dynamics Corporation $GD Shares Sold by Danske Bank A S

Danske Bank A S reduced its stake in General Dynamics Corporation by 7.7% in the second quarter, selling 6,387 shares and now owning 76,377 shares valued at $27.06 million. Despite this, other institutional investors have increased their holdings, and 86.14% of the company's stock …

416,438 Shares in General Dynamics Corporation $GD Purchased by Deutsche Bank AG

Deutsche Bank AG has acquired a new stake of 416,438 shares in General Dynamics Corporation (NYSE:GD), valued at approximately $147.5 million, representing about 0.15% of the company's stock. Other institutional investors have also adjusted their positions in General Dynamics. Analyst ratings for GD currently …

First National Bank of Omaha Invests $1.20 Million in General Dynamics Corporation $GD

First National Bank of Omaha has acquired a new stake of 3,434 shares in General Dynamics Corporation, valued at approximately $1.20 million. Other institutional investors have also adjusted their holdings, and company insiders have recently sold significant amounts of stock. General Dynamics reported strong …

Aurora Investment Counsel Takes Position in Halozyme Therapeutics, Inc. $HALO

Aurora Investment Counsel has acquired a new stake of 18,233 shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO), valued at approximately $1.43 million, during the second quarter. This move is part of broader institutional investor activity, with several other firms also adjusting their holdings in the …

Great Lakes Advisors LLC Takes $5.64 Million Position in First Interstate BancSystem, Inc. $FIBK

Great Lakes Advisors LLC has acquired a new stake of 146,228 shares in First Interstate BancSystem, Inc. (NASDAQ:FIBK), valued at approximately $5.64 million, representing 0.15% ownership. This move comes as other institutional investors have also adjusted their positions in the company, while company insiders …

TORO 18 HOLDINGS LLC Sells 66,896 Shares of Universal Electronics Inc (UEIC)

TORO 18 HOLDINGS LLC, a 10% owner of Universal Electronics Inc (UEIC), sold 66,896 shares of the company's common stock at $5.13 per share on August 19, 2026. This transaction continues a pattern of insider selling, with 10 insider sells and no buys over …

Price to book forward of TG Therapeutics, Inc. – BX:NKB2

This article provides a brief financial data point for TG Therapeutics, Inc. (BX:NKB2) focusing on its forward price-to-book ratio. The content indicates a period value, change, and percentage change for this metric, suggesting it is a snapshot of recent financial performance. The article appears …

Cardiol Therapeutics Inc (CRDL) Stock Price, Trades & News

Janux (JANX) Latest Quarter: EPS Lands Above Forecast; Market Reaction: Shares Finish 3.30% Higher on the Day - Estimate Revision Count

Salzer Electronics schedules 41st AGM for September 12, 2026

Fulgent Genetics (NASDAQ:FLGT) Share Price Crosses Below Fifty Day Moving Average - Here's What Happened

Fulgent Genetics (NASDAQ:FLGT) saw its share price drop below its 50-day moving average, trading as low as $18.96 before closing at $19.74. The company missed its quarterly earnings expectations, reporting an adjusted loss of $0.58 per share against an estimated loss of $0.46, and …

Is Home BancShares (HOMB) A Bargain Or Fully Priced At $30?

Ovid Therapeutics Inc. (OVID) Latest Stock News & Headlines

Shield Therapeutics cuts H1 loss as ACCRUFeR growth drives revenue higher

VSTECS: First-half 2026 revenue grew 15.6% and net profit rose 16%, driven by broad-based segment gains

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Recommendation of "Hold" by Brokerages

Fate Therapeutics, Inc. (NASDAQ:FATE) has received a consensus "Hold" rating from eight brokerages, with an average 12-month price target of $5.90. The biopharmaceutical company, which focuses on iPSC-derived cellular immunotherapies, reported quarterly revenue of $2.08 million and an adjusted loss of $0.25 per share, …

David Kirn plans $1.16M 4D Molecular (NASDAQ: FDMT) stock sale

David Kirn, an officer at 4D Molecular Therapeutics, Inc. (FDMT), plans to sell 69,076 shares of Class A Common Stock valued at approximately $1.16 million through Goldman Sachs & Co. LLC. This sale is part of a Rule 10b5-1(c) selling plan initiated on January …

United Therapeutics (UTHR) CEO sells shares under preset trading plan

Martine Rothblatt, Chairperson & CEO of United Therapeutics (UTHR), through a family trust, exercised 9,500 stock options at $135.42 per share and then sold the corresponding 9,500 common shares in multiple open-market trades at weighted average prices around the low-$500s per share on August …

Relay Therapeutics, Inc. $RLAY Shares Bought by Bank of America Corp DE

Bank of America Corp DE significantly increased its stake in Relay Therapeutics (NASDAQ:RLAY) by 86.1% during the first quarter, now owning 1.01% of the company's stock valued at $19.28 million. Other institutional investors and hedge funds also made substantial changes to their positions, with …

Fulcrum (FULC) Quarter in Focus: The Available Earnings Metric Delivers a Beat in the Current Update; Market Response: Shares Finish 1.03% Higher on the Day - Earnings Revision Report

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of "Moderate Buy" by Analysts

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $56.08, exceeding its current share price of $41.70. While recent analyst actions were mixed, including Guggenheim raising its target to $100 and Cantor Fitzgerald …

SAB (SABS) Earnings Update: EPS Prints Above Forecast in the Current Update; Market Move: Shares Move Lower 0.26% in the Latest Session - ROE Trend Analysis

BridgeBio (BBOT) Financial Results: The EPS Result Is Above Expectation in the Current Update; Share Response: Shares Move 7.26% Up - One-Time Gain Impact

Artiva (ARTV) Earnings Update: The Bottom-Line Figure Outpaces Its Comparison on the Day; Post-Report: The Market Price Moves 0.17% Higher for the Current Session - EPS Revision Trend

Prenetics (PRE) Earnings Reading: Profit Per Share Clears Its Benchmark on the Day; Closing Reaction: The Stock Ends Down 3.30% in Latest Trading - Financial Health Score

Cleo Diagnostics Posts Deeper Annual Loss as Revenue Falls and Asset Backing Weakens

Shield Therapeutics narrows losses as ACCRUFeR® growth and global milestones lift H1 revenue

Quest Diagnostics (DGX) Could Be 30% Below Fair Value After Upgrade And WHOOP Deal

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Quest Diagnostics (DGX) is back in focus after a fresh analyst rating upgrade and a new role powering WHOOP Advanced Labs, which includes …

Anika Therapeutics (NASDAQ:ANIK) Stock Price Passes Above Two Hundred Day Moving Average - Here's Why

Anika Therapeutics (NASDAQ:ANIK) stock recently surpassed its 200-day moving average of $14.84, closing at $21.26, despite a 1.4% dip during the session. Analyst sentiment has improved, with B. Riley raising its price target to $21 and Wall Street Zen and Zacks upgrading the stock …

Top Smart Logistics Global (SLGB) Competitors 2026

CSPC Pharmaceutical's Attributable Profit More Than Doubles in H1; Shares Jump 14%

REG - AB Dynamics PLC - Acquisition of eMpulse Test Systems LLC

Is Spyre Therapeutics (SYRE) Fully Priced After Its SPY772 Program And SKYLIGHT Trial Launch?

Spyre Therapeutics (SYRE) has launched its SPY772 combination program and initiated the SKYLIGHT Phase 2 trial for Hidradenitis Suppurativa, targeting dual inhibition of TL1A and IL-17A/F. Despite strong recent share price performance and a P/B ratio of 10.1x (compared to the US biotech average …

STMicroelectronics NV (STM) Stock Down 3.6% but Still Overvalued -- GF Score: 80/100

STMicroelectronics NV (STM) shares recently fell 3.6% to $50.41, yet GuruFocus assesses the stock as significantly overvalued with a GF Value™ of $31.30. Despite a strong GF Score™ of 80/100, driven by financial strength and profitability, its valuation rank is low, and the current …

Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform (NASDAQ:TRVI)

Trevi Therapeutics is positioned to leverage its drug Haduvio to target IPF-related chronic cough, with plans to expand into non-IPF ILD and refractory chronic cough. The company's strategy focuses on concentrated pulmonology networks, enabling efficient market entry and growth. With positive Phase II data, …

Synaptics VP Esther Song sells $45,307 in company stock

Esther Song, VP and Corporate Controller at Synaptics Inc., sold $45,307 worth of company stock through a pre-arranged trading plan, while also acquiring shares through vesting restricted stock units and disposing of others for tax obligations. This comes as Synaptics stock has seen a …